ICUS Weekly News Monitor 4-22-2016

1. Healio Rheumatology,  Apr 20, 2016,  Contrast-enhanced ultrasound may be effective in diagnosing large vessel vasculitis     By Shirley Pulawski
 
2.  Healio  HCV Next,  April 2016,  The March Toward Elastography for Assessing Fibrosis in HCV
 
3.  Medgadget.com,  April 19, 2016,  Key Factors Driving Pre-Clinical Imaging Market
 
____________________________________________
Healio
Rheumatology
Germanò G, et al. Arth Care Res. 2016;doi:10.1002/acr.22906.
Apr 20, 2016
 
Contrast-enhanced ultrasound may be effective in diagnosing large vessel vasculitis
By Shirley Pulawski
 
Carotid contrast-enhanced ultrasound vascularization grade and grade pf vascular inflammation shown on 18F-FDG positron emission tomography correlated well in patients with large vessel vasculitis, according to recently published research.
 
Researchers enrolled 31 patients with large vessel vasculitis (LVV), including four patients who were evaluated twice over a 12-month period. Standard color Doppler ultrasound (CDUS) evaluations of extra-cranial carotid arteries were administered to all patients and intima media thickness was measured at the far wall of both carotid arteries in proximity to the bifurcation. Vasculitis was determined in the presence of a hypoechoic, circumferential homogenous wall thickening, while inhomogenous, eccentric, thickening of the partly calcified arterial wall was deemed athermatosis. Criteria defined by Drielsma et al was used to define atherosclerotic
carotid plaques.
 
Within 5 to 10 seconds following the standard CDUS examination, an ultrasound contrast agent was infused to assess the right carotid artery with contrast-enhanced ultrasound (CEUS) and the degree of vascularization was classified.
 
Within 3 days of CEUS evaluation, patients underwent 18F-FDG PET/CT scans after fasting for 4 or more hours prior to injection.
 
Erythrocyte sedimentation rates and C-reactive protein were elevated during the testing point in 19 of the examinations. Abnormal vascular uptake was demonstrated in 10 examinations in the right carotid artery and in different vascular areas in nine examinations.
 
Patients with grade 2 vascularization at CEUS were more likely to have intima media thickness above 1 mm and FDG carotid uptake of 2 or greater and the maximum standardized uptake value (SUV) and the mean SUV in the right carotid artery and mean SUV in the superior vena cava were significantly higher in patients with severe vascularization on CEUS.
 
“In conclusion, CEUS is a cheap, non-invasive tool useful to examine large vessel wall vascularization in LVV,” the researchers wrote. “The correlation between CEUS and 18F-FDG uptake suggests an association between vascularization and inflammation and supports the use of CEUS as a noninvasive method able to detect disease activity in patients with LVV.”
 
____________________________________________
Healio
HCV Next
April 2016
 
The March Toward Elastography for Assessing Fibrosis in HCV
Http://www.healio.com/hepatology/hepatitis-c/news/print/hcv-next/%7Bb269de70-be1e-4776-93de-0694983e8d8b%7D/the-march-toward-elastography-for-assessing-fibrosis-in-hcv
 
There are a number of ways to assess fibrosis in HCV, but none are perfect. The long-time mainstay of measuring fibrosis — liver biopsy — may eventually fall out of fashion in the wake of advances in noninvasive measures. The clinical community has been seeking its replacement for two decades, and has largely turned to imaging techniques. Magnetic resonance and transient ultrasound elastography have become the twin pillars of the field. HCV Next spoke with a handful of experts regarding elastography, and it became clear that addressing serum biomarkers and other scoring systems along with ongoing use of biopsy is necessary. Each method comes with drawbacks. The arguments against these various non-invasive ways of assessing fibrosis range from cost, to small sample size, to limited ability to view the liver in its entirety……..Clinicians in the U.S. rely heavily on magnetic resonance elastography (MRE), whereas various forms of ultrasound elastography are used abroad, according to SimonTaylor-Robinson, MD, PhD, clinical consul for the Faculty of Medicine at Imperial College of London. “Ultrasound contrast agents are the gold standard outside the U.S., largely because access to MR machines is less common in other parts of the world,” he said. “In the U.S., people tend not to use ultrasound.”
 
________________________________
Medgadget.com
April 19, 2016
 
Key Factors Driving Pre-Clinical Imaging Market
Transparency Market Research Releases
 
The global pre-clinical imaging market has been exhibiting immense growth since the last few years and the trend is expected to continue in the coming years. The advancement in molecular imaging technologies and the increasing adoption of pre-clinical imaging technology as a reliable drug development tool are likely to propel this market in the nearing future.
 
The global market for pre-clinical imaging is broadly analyzed on the basis of the imaging system, the imaging reagent, technology, and the regional spread of this market. Based on the imaging system, the market is classified into standalone imaging systems and multimodal imaging systems.
 
Based on the imaging reagent, the market is categorized into optical imaging agents, MRI contrasting reagents, CT contrast reagents, nuclear imaging agents, and ultrasound contrast reagents. Technology wise, the market includes PET + SPECT + CT, PET + MRI, and SPECT + MRI as the major segments.
 
On the regional basis, the worldwide pre-clinical imaging market is segmented into North America, Asia Pacific, Europe, and the Rest of the World.
 
This report on the global pre-clinical imaging market attempts to provide a comprehensive overview of this market on the basis of its current and historical performance as well as its future prospects. Driving forces, limitations, latest and upcoming trends, and opportunities of this market have also been discussed at length in this research study.
 
Overview of the Global Pre-Clinical Imaging Market
 
The global pre-clinical imaging market has experienced a surge in its valuation in the recent times. Various macro-environmental factors such as technical innovation and government grants and funding have boosted this market significantly over the past few years.
 
The standalone imaging systems market includes micro-MRI, micro-CT, micro-ultrasound, nuclear imaging, and optical imaging. Multimodal nuclear imaging devices and multimodal optical imaging devices are the major segments of the multimodal imaging systems market.
 
North America leads the worldwide pre-clinical imaging systems and is closely followed by Europe. Asia Pacific and the Rest of the World are also projected to emerge as lucrative markets for pre-clinical imaging in the near future.
 
Overall, the global market is witnessing a steady rise in demand. However, the increasing prices of imaging systems and the lack of awareness regarding technology in developing economies are hampering the market’s growth. The consolidation in the worldwide pharmaceutical industry is also expected to restrict this market from rising steadily in the forthcoming years.
 
Companies mentioned in the research report:
 
Bioscan Inc., PerkinElmer Inc., Siemens AG, Aspect Imaging, Life Technologies Corp., and Gamma Medica Inc. are leading the worldwide pre-clinical imaging market.

ICUS Sponsors

ICUS gratefully acknowledges its 2017 sponsors:

dentons-logo2

silver-level

Toshiba Medical logo resized

philips-icus-logo

samsung-logo

siemens-new-original

mindray

Contact ICUS

  • Address: 1900 K Street, N.W.
    Washington, DC 20006-1102, USA
  • Telephone: 202-408-6199

About ICUS

ICUS is the world’s only professional society exclusively devoted to contrast-enhanced ultrasound (CEUS) medical imaging technology.

Learn more...

You are here: Home ICUS Weekly News Monitors ICUS Weekly News Monitor 4-22-2016